Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

Thomas Powles, Robert J. Motzer, Bernard Escudier, Sumanta Pal, Christian Kollmannsberger, Joanna Pikiel, Howard Gurney, Sun Young Rha, Se Hoon Park, Poul F. Geertsen, Marine Gross-Goupil, Enrique Grande, Cristina Suarez, David W. Markby, Alan Arroyo, Mark Dean, Toni K. Choueiri, Daniel George

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. Methods: Outcomes were evaluated for subgroups defined by prior therapy with sunitinib or pazopanib as the only prior VEGFR inhibitor, or prior anti-PD-1/PD-L1 therapy. Results: For the prior sunitinib subgroup (N = 267), median PFS for cabozantinib versus everolimus was 9.1 versus 3.7 months (HR 0.43, 95% CI 0.32–0.59), ORR was 16% versus 3%, and median OS was 21.4 versus 16.5 months (HR 0.66, 95% CI 0.47–0.93). For the prior pazopanib subgroup (N = 171), median PFS for cabozantinib versus everolimus was 7.4 versus 5.1 months (HR 0.67, 95% CI 0.45–0.99), ORR was 19% versus 4%, and median OS was 22.0 versus 17.5 months (HR 0.66, 95% CI 0.42–1.04). For prior anti-PD-1/PD-L1 therapy (N = 32), median PFS was not reached for cabozantinib versus 4.1 months for everolimus (HR 0.22, 95% CI 0.07–0.65), ORR was 22% versus 0%, and median OS was not reached versus 16.3 months (HR 0.56, 95% CI 0.21–1.52). Conclusions: Cabozantinib was associated with improved clinical outcomes versus everolimus in patients with advanced RCC, irrespective of prior therapy, including checkpoint inhibitor therapy.

LanguageEnglish
Pages663-669
Number of pages7
JournalBritish Journal of Cancer
Volume119
Issue number6
DOIs
Publication statusPublished - 11 Sep 2018

Fingerprint

Renal Cell Carcinoma
Disease-Free Survival
Survival
Therapeutics
Everolimus
cabozantinib
Survival Rate

Bibliographical note

Copyright the Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Cite this

Powles, Thomas ; Motzer, Robert J. ; Escudier, Bernard ; Pal, Sumanta ; Kollmannsberger, Christian ; Pikiel, Joanna ; Gurney, Howard ; Rha, Sun Young ; Park, Se Hoon ; Geertsen, Poul F. ; Gross-Goupil, Marine ; Grande, Enrique ; Suarez, Cristina ; Markby, David W. ; Arroyo, Alan ; Dean, Mark ; Choueiri, Toni K. ; George, Daniel. / Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. In: British Journal of Cancer. 2018 ; Vol. 119, No. 6. pp. 663-669.
@article{0c40e1f45980424e8b5288b8d9cdbb4f,
title = "Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma",
abstract = "Background: In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. Methods: Outcomes were evaluated for subgroups defined by prior therapy with sunitinib or pazopanib as the only prior VEGFR inhibitor, or prior anti-PD-1/PD-L1 therapy. Results: For the prior sunitinib subgroup (N = 267), median PFS for cabozantinib versus everolimus was 9.1 versus 3.7 months (HR 0.43, 95{\%} CI 0.32–0.59), ORR was 16{\%} versus 3{\%}, and median OS was 21.4 versus 16.5 months (HR 0.66, 95{\%} CI 0.47–0.93). For the prior pazopanib subgroup (N = 171), median PFS for cabozantinib versus everolimus was 7.4 versus 5.1 months (HR 0.67, 95{\%} CI 0.45–0.99), ORR was 19{\%} versus 4{\%}, and median OS was 22.0 versus 17.5 months (HR 0.66, 95{\%} CI 0.42–1.04). For prior anti-PD-1/PD-L1 therapy (N = 32), median PFS was not reached for cabozantinib versus 4.1 months for everolimus (HR 0.22, 95{\%} CI 0.07–0.65), ORR was 22{\%} versus 0{\%}, and median OS was not reached versus 16.3 months (HR 0.56, 95{\%} CI 0.21–1.52). Conclusions: Cabozantinib was associated with improved clinical outcomes versus everolimus in patients with advanced RCC, irrespective of prior therapy, including checkpoint inhibitor therapy.",
author = "Thomas Powles and Motzer, {Robert J.} and Bernard Escudier and Sumanta Pal and Christian Kollmannsberger and Joanna Pikiel and Howard Gurney and Rha, {Sun Young} and Park, {Se Hoon} and Geertsen, {Poul F.} and Marine Gross-Goupil and Enrique Grande and Cristina Suarez and Markby, {David W.} and Alan Arroyo and Mark Dean and Choueiri, {Toni K.} and Daniel George",
note = "Copyright the Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",
year = "2018",
month = "9",
day = "11",
doi = "10.1038/s41416-018-0164-0",
language = "English",
volume = "119",
pages = "663--669",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Springer, Springer Nature",
number = "6",

}

Powles, T, Motzer, RJ, Escudier, B, Pal, S, Kollmannsberger, C, Pikiel, J, Gurney, H, Rha, SY, Park, SH, Geertsen, PF, Gross-Goupil, M, Grande, E, Suarez, C, Markby, DW, Arroyo, A, Dean, M, Choueiri, TK & George, D 2018, 'Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma', British Journal of Cancer, vol. 119, no. 6, pp. 663-669. https://doi.org/10.1038/s41416-018-0164-0

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. / Powles, Thomas; Motzer, Robert J.; Escudier, Bernard; Pal, Sumanta; Kollmannsberger, Christian; Pikiel, Joanna; Gurney, Howard; Rha, Sun Young; Park, Se Hoon; Geertsen, Poul F.; Gross-Goupil, Marine; Grande, Enrique; Suarez, Cristina; Markby, David W.; Arroyo, Alan; Dean, Mark; Choueiri, Toni K.; George, Daniel.

In: British Journal of Cancer, Vol. 119, No. 6, 11.09.2018, p. 663-669.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

AU - Powles, Thomas

AU - Motzer, Robert J.

AU - Escudier, Bernard

AU - Pal, Sumanta

AU - Kollmannsberger, Christian

AU - Pikiel, Joanna

AU - Gurney, Howard

AU - Rha, Sun Young

AU - Park, Se Hoon

AU - Geertsen, Poul F.

AU - Gross-Goupil, Marine

AU - Grande, Enrique

AU - Suarez, Cristina

AU - Markby, David W.

AU - Arroyo, Alan

AU - Dean, Mark

AU - Choueiri, Toni K.

AU - George, Daniel

N1 - Copyright the Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2018/9/11

Y1 - 2018/9/11

N2 - Background: In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. Methods: Outcomes were evaluated for subgroups defined by prior therapy with sunitinib or pazopanib as the only prior VEGFR inhibitor, or prior anti-PD-1/PD-L1 therapy. Results: For the prior sunitinib subgroup (N = 267), median PFS for cabozantinib versus everolimus was 9.1 versus 3.7 months (HR 0.43, 95% CI 0.32–0.59), ORR was 16% versus 3%, and median OS was 21.4 versus 16.5 months (HR 0.66, 95% CI 0.47–0.93). For the prior pazopanib subgroup (N = 171), median PFS for cabozantinib versus everolimus was 7.4 versus 5.1 months (HR 0.67, 95% CI 0.45–0.99), ORR was 19% versus 4%, and median OS was 22.0 versus 17.5 months (HR 0.66, 95% CI 0.42–1.04). For prior anti-PD-1/PD-L1 therapy (N = 32), median PFS was not reached for cabozantinib versus 4.1 months for everolimus (HR 0.22, 95% CI 0.07–0.65), ORR was 22% versus 0%, and median OS was not reached versus 16.3 months (HR 0.56, 95% CI 0.21–1.52). Conclusions: Cabozantinib was associated with improved clinical outcomes versus everolimus in patients with advanced RCC, irrespective of prior therapy, including checkpoint inhibitor therapy.

AB - Background: In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. Methods: Outcomes were evaluated for subgroups defined by prior therapy with sunitinib or pazopanib as the only prior VEGFR inhibitor, or prior anti-PD-1/PD-L1 therapy. Results: For the prior sunitinib subgroup (N = 267), median PFS for cabozantinib versus everolimus was 9.1 versus 3.7 months (HR 0.43, 95% CI 0.32–0.59), ORR was 16% versus 3%, and median OS was 21.4 versus 16.5 months (HR 0.66, 95% CI 0.47–0.93). For the prior pazopanib subgroup (N = 171), median PFS for cabozantinib versus everolimus was 7.4 versus 5.1 months (HR 0.67, 95% CI 0.45–0.99), ORR was 19% versus 4%, and median OS was 22.0 versus 17.5 months (HR 0.66, 95% CI 0.42–1.04). For prior anti-PD-1/PD-L1 therapy (N = 32), median PFS was not reached for cabozantinib versus 4.1 months for everolimus (HR 0.22, 95% CI 0.07–0.65), ORR was 22% versus 0%, and median OS was not reached versus 16.3 months (HR 0.56, 95% CI 0.21–1.52). Conclusions: Cabozantinib was associated with improved clinical outcomes versus everolimus in patients with advanced RCC, irrespective of prior therapy, including checkpoint inhibitor therapy.

UR - http://www.scopus.com/inward/record.url?scp=85053437700&partnerID=8YFLogxK

U2 - 10.1038/s41416-018-0164-0

DO - 10.1038/s41416-018-0164-0

M3 - Article

VL - 119

SP - 663

EP - 669

JO - British Journal of Cancer

T2 - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -